Carcinoma of Unknown Primary — Trials

Carcinoma of Unknown Primary — Trials · CancerIndex

Clinical trials

Registered studies

14,232 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,156
Recruiting: 2,259
Ph III recruiting: 269
Growth YoY: +12.3%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,893)

clinicaltrialsPublishedShowing 401–450 of 14,232 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07825597	Indocyanine Green With Near Infrared Imaging for Intraoperative Visualization of Head and Neck Squamous Cell Carcinoma	not yet recruiting	—	25	Washington University School of MedicineOTHER	1	Sep 17, 2026	clinicaltrials
NCT02974738	A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)	active not recruiting	Phase 1	120	Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY